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Abstract
Background: Adjunctive use of nutraceuticals in human cancer has shown promise, but little work has been done
in canine neoplasia. Previous human research has shown that polyphenols and carotenoids can target
multiple pathways in vitro and in vivo. These compounds could synergize or antagonize with currently used
chemotherapies, either increasing or decreasing the effectiveness of these drugs. Considering the routine and
well controlled feeding practices of most dogs, the use of nutraceuticals incorporated into pet food is
attractive, pending proof that the extracts are able to improve remission rates. The aim of this study was to
examine five feed ingredients for antiproliferative effects, as well as the interaction with toceranib phosphate
and doxorubicin hydrochloride, when treating canine neoplastic cell lines in vitro.
Results: Screening using MTT proliferation assays showed that green tea, turmeric, and rosemary extracts
were the most effective. Turmeric extract (TE) was the most potent and exhibited synergy with a rosemary
extract (RE) at concentrations from 1 to 25 μg mL−1. This combination had an additive or synergistic effect
with chemotherapeutic agents at selected concentrations within each cell line. No significant effects on cell
viability were observed when the combination therapy was used with normal primary cells.
Conclusions: The use of turmeric and rosemary extracts in combination may be worthwhile to investigate in
the pre-clinical and clinical neoplastic considering there are no negative effects on traditional chemotherapy
treatment. Further studies into the pharmacokinetics and mechanisms of action of these extracts should be
investigated.
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Background
Neoplasia is the cause of death in 20–30 percent of dogs
in the United States, and the incidence and mortality in-
creases to 50 % in dogs over the age of ten [1–3]. Risk
factors for developing cancer vary based on age, breed,
sex, medical history, and nutrition [4]. The incidence
and, in some cases, tumor origin are different between
dogs and humans, with lymphoma, mast cell disease,
osteosarcoma, and mammary neoplasia being particu-
larly prevalent in dogs [5]. Current treatments rely on
the use of chemotherapeutics, radiation therapy, and,
when practical, surgical interventions. The efficacy of
such treatments varies greatly and relies heavily on the
stage of cancer progression when treatment is provided,
genetic predispositions, and tolerance to the chemother-
apy and/or radiation treatments.
Most chemotherapeutic treatments are limited and
target DNA replication (cell cycle), cellular metabolism
or a single regulatory pathway. In the case of high grade
and refractory tumors, multiple drug combinations are
often used in order to achieve remission. As the number
of treatment modalities increase there can be com-
pounding side effects that are not always well tolerated
by patients [6].
The use of natural compounds, or nutraceuticals, in
combination with traditional chemotherapy might pro-
vide value, and 40 % of pet owners admit to using nutri-
tional supplements as a complementary therapy [7].
Natural products have been used in the initial design of
chemotherapies, with well over half of all compounds
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synthesized or screened being more potent derivations
of natural products [8]. The effects of these compounds,
whether natural or synthetically made, act through a var-
iety of mechanisms that may contribute to the anti-
cancer properties [9, 10]. In fact, a single compound
might be able to induce apoptosis through several differ-
ent pathways [11]. Much of the natural product re-
search performed has been on human or rodent cell
lines, particularly of epithelial origin, with little
research being done on canine cell lines [12]. More
research is necessary to determine the specific effects
of these natural products in canine cells and in com-
bination with chemotherapies commonly used in vet-
erinary medicine, as there is a paucity of information
in veterinary medicine [13–15].
Plant extracts consist of various polyphenols, terpines,
stilbenoids and carotenoids [16]. Several epidemiological
studies in humans have found benefits to the inclusion
of polyphenol and carotenoid rich fruits and vegetables
in the diet [17, 18]. A case–control study has been com-
pleted in dogs, and the results indicated an inverse rela-
tionship between the consumption of vegetables and the
risk of developing transitional cell carcinoma of the
urinary bladder in Scottish Terriers [19]. The potential
use of certain polyphenols and carotenoids as a treat-
ment option is ongoing in pre-clinical trials with
treatment of human epithelial carcinomas on the
horizon [20–22]. However; it is necessary to investi-
gate the potential effectiveness in canine cancers
which represent other cellular lineages with round,
mesenchymal and epithelial neoplasias all being
prevalent. In veterinary patients, there have been few
intervention studies to examine nutraceutical dietary addi-
tions, with two studies examining possible treatment of
lymphoma in dogs [23, 24]. Considering that the typical
daily feeding patterns of companion dogs are consistent
(once or twice per day), the potential for incorporation of
natural anti-carcinogenic ingredients is feasible, so long as
the added herbal, fruit, or vegetable extract is considered
generally reliable and safe by the American Association of
Feed Control Officials [25].
The objective of this study was to examine the anti-
proliferative effects of five commonly used natural food
extracts chosen from an initial cytotoxic screening,
which could be utilized in commercial dog food, on
canine mastocytoma, mammary carcinoma, and osteo-
sarcoma cell lines. After defining efficacy of the leading
extracts we set forth to determine if combinations of the
most potent extract, turmeric extract [85 % curcumi-
noids] (TE) could work synergistically with the other
extract, and whether these extracts had an additive effect
when used in conjunction with the chemotherapeutic
drugs most often utilized in the treatment of each neo-
plastic disease represented in the cell culture systems.
Methods
Substances
Natural extracts were received directly from the manu-
facturer and the content of each compound of interest
based on the manufacturers’ purity analysis was verified
by a secondary laboratory (Table 1). Extracts were
dissolved at 20 mg mL−1 in 100 % dimethyl sulfoxide
(DMSO; Sigma-Aldrich, St. Louis, MO, USA) to obtain
stock solutions before every experiment. Chemotherapeutic
agents used were toceranib phosphate (PalladiaTM, Zoetis
Animal Health, Florham Park, NJ) and doxorubicin hydro-
chloride (Sigma Aldrich, St Louis, MO); fresh dilutions
were made from stock before each experiment.
Cell culture
Three canine neoplastic primary cell lines were used,
representing round, mesenchymal and epithelial tumor
types: mastocytoma C2 (University of California, San
Fransisco, USA), mammary gland carcinoma CMT-12
(Auburn University, Alabama, USA), and osteosarcoma
D17 (#CCL-183; ATCC, Manassas, VA, USA). The cell
lines were grown on tissue culture-treated plates (La-
boratory Product Sales [LPS], Rochester, NY, USA) with
appropriate medium containing 10 % heat inactivated
fetal bovine serum (HI-FBS; Invitrogen, Carlsbad, CA,
USA) and 1 % antibiotic-antimycotic (Invitrogen). Cell
lines were grown at 37 °C and 5 % CO2 for all experi-
ments and passage of cells, unless otherwise noted. Ca-
nine primary dermal fibroblasts (Applied Biological
Materials [ABM], Richmond, BC, Canada) were used to
investigate effects on normal cells and were propagated
Table 1 Characteristics of natural extracts








Black pepper Piper nigrum Fruit Piperine 95.02 % Sabinsa VetPerine FP-0215–06 C130329
Green tea Camellia sinensis Leaf EGCG 45.76 % Naturex Green tea extract EA140362 A043/008/A13
Pomegranate Punica granatum Skin Punicalagins 35.60 % Polinat Pomegranate extract
[40 % punicosides]
P40P P40P13–2102
Rosemary Rosmarinus officinalis Leaf Carnosic acid 66.90 % Vitiva Rosemary extract INOLENS70 302036 LAB.13–036001
Turmeric Curcuma longa Root Curcuminoids 87.59 % Naturex Turmeric extract DA251471 A060/006/D13
aPurity value represents the percent of the main compound of interest in each extract as determined by manufacturer
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and maintained on PriCoat T25 flasks (ABM) in Prigrow
II medium (ABM) containing 10 HI-FBS (Invitrogen)
and 1 % penicillin/streptomycin (Invitrogen).
MTT proliferation assay
Cells were plated at a density of 4 × 103 cells per well on
96-well tissue culture-treated flat bottom plates (LPS)
and incubated overnight in complete medium. Cells
were treated the following day with DMSO vehicle con-
trol or extract using a twofold serial dilution for eight
final concentrations ranging from 0.4 to 100 μg mL−1 for
48 h representing physiological and supra-physiological
concentrations to assess all extracts for potential effect-
iveness at reducing cellular proliferation. A twofold
serial dilution of chemotherapy was also tested ranging
from 1.7 to 100 nM toceranib phosphate for the C2 cell
line, and 0.03 to 2 μM doxorubicin hydrochloride for the
CMT-12 and D17 cell lines. To quantify cellular prolifera-
tion, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT dye; Alfa Aesar, Ward Hill, MA, USA) as-
says were performed by adding 30 μL of MTT dye
(5 mg mL−1 in phosphate-buffered saline solution) to each
well and incubating at 37 °C for 1 h. Media were then aspi-
rated and the cells were solubilized in 200 μL of isopropa-
nol. The optical density of each well was analyzed on a
spectrophotometric plate reader (Epoch; Biotek, Winooski,
VT, USA) at a wavelength of 570 nm as previously
described [26]. Single extract experiments were assayed in
duplicate in four independent experiments.
Synergy between extracts was examined using combi-
nations of two extracts at six concentrations: 0.8, 1.7,
3.1, 6.3, 12.5, or 25 μg mL−1 as a representation of po-
tentially high end physiological concentrations. All pair-
wise combinations of extract concentrations were tested.
The percent proliferating cells of control for each treat-
ment was pooled from all experiments and is reported
as mean ± standard error of the mean.
Interaction with toceranib phosphate/doxorubicin
hydrochloride using proliferation assay
Cells were plated at a density of 4 × 103 cells per
well on 96-well tissue culture-treated plates (LPS) and
incubated overnight in complete medium. Cells were
treated the following day with 50 μL of a combination
of TE (0.8, 1.7, 3.1, or 6.3 μg mL−1), RE (0.8, 1.7, 3.1,
or 6.3 μg mL−1), and chemotherapeutic drug. The C2
cell line was treated with toceranib phosphate (3.1,
6.3, 12.5, 25, 50, 100 nM) and the CMT-12 and D17
cell lines were treated with doxorubicin hydrochloride
(0.03, 0.06, 0.13, 0.25, 0.5, 1, 2 μM). DMSO was used
as a vehicle control for all treatments. Cells were
treated for 48 h before performing MTT assays. Wells
treated with DMSO were considered to represent
100 % proliferating cells. All combinations were tested
in duplicate in two independent experiments.
Trypan blue exclusion assay of cell viability
The trypan blue exclusion assay was performed on
canine primary dermal fibroblasts (CDF) due to the slow
rate of proliferation and low metabolic activity of these
normal canine cells, precluding productive MTT assays.
The effects of extract treatments were compared to the
results obtained on the C2, CMT-12, and D17 cell lines.
For the CDF cells, Applied Cell Extracellular Matrix
(ABM) was applied overnight to 24-well tissue culture-
treated plates (LPS). For all cell lines, cells were plated at
a density of 5 ×103 cells per well and incubated until
60 % confluent before treatment with DMSO vehicle
control, 6.3 μg mL−1 TE, 6.3 μg mL−1 RE, or a combin-
ation of 3.1 μg mL−1 each of TE and RE. After 48 h of
treatment, cells were collected and centrifuged at
1,900 g for 10 min. With the exception of the C2 cell
line, cells were detached with 0.05 % Trypsin/EDTA.
The cell pellet was resuspended in 0.1 % trypan blue
(Sigma) in phosphate-buffered saline solution and 1 %
FBS, loaded on a hemocytometer, and visualized on an
inverted microscope. Cells which stained blue were con-
sidered non-viable. All treatments were performed in
triplicate and the percent of viable cells were averaged.
All values were standardized to the vehicle control treat-
ment which was considered to represent 100 % viable
cells.
Data management and calculations
Raw data from proliferation assays (optical density of
each well) were normalized to the vehicle alone treat-
ment for individual assays, considered to represent
100 % proliferating cells (single or combined treatment).
The percent proliferating cells was then averaged across
each replicate. The IC50 for each extract was then calcu-
lated across experiments by Probit analysis.
The compound interactions were calculated by mul-
tiple drug effect analysis using CalcuSyn software
(v.2.11; Biosoft, Cambridge, GB, United Kingdom) which
employs the median equation principle according to the
methodology described by Chou and Talalay [27] to de-
termine a combination index (CI) value by the formula:




þ Dð Þ1 Dð Þ2
Dxð Þ1 Dxð Þ2
Where (D)1 and (D)2 are the doses of both compounds
in combination and (Dx)1 and (Dx)2 are the doses of each
compound alone at x percent of inhibition. CI values
≤0.9 indicate synergism, a CI value >0.9 and <1.1 indi-
cates an additive effect, and CI values ≥1.1 indicate
antagonism.
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Statistical analysis
All statistical analysis on the outcome of percent prolif-
erating cells as measured by MTT assay was performed
using JMP Pro (v. 11.2.1; SAS Institute Inc., Cary, NC,
USA). The residuals of the statistical model were evalu-
ated for normality and found to be not normally distrib-
uted. Therefore, non-parametric Kruskal-Wallis test was
used to compare differences in percent proliferating cells
for every treatment concentration used within each cell
line across experiments. Comparisons between each
treatment group and vehicle control group were carried
out using the Steel method adjusting alpha risk for mul-
tiple comparisons.
For the outcome of percent viability determined by the
trypan blue exclusion assay, residuals of the statistical
model were found to be normally distributed, and there-
fore analyzed using analysis of variance with Tukey’s
method for comparison between all treatments, control-
ling for multiple comparisons. Differences were consid-
ered statistically significant at p < 0.05.
Results
Single treatment versus dual combination treatment on
three types of cancer cell lines
All three cell lines were most sensitive to TE, with an
IC50 below 13 μg mL
−1 and a significant decrease in cell
proliferation at concentrations of at least 0.8 μg mL−1 in
the C2 cell line, and at concentrations of 6.3 μg mL−1
and higher in both the CMT-12 and D17 cell lines (p <
0.0001). RE also had an effect with IC50 less than
14 μg mL−1 in all three cell lines, and a significant de-
crease in cell proliferation at a concentration of
6.3 μg mL−1 and above in the C2 cell line (p = 0.0203)
and at 12.5 μg mL−1 and above in the CMT-12 and D17
cell lines (p < 0.0001). Low concentrations of RE caused
a minor increase in proliferation when used alone: 9 %
increase with 0.8 μg mL−1 in C2; an average of 11 % in-
crease with concentrations of 3.1 μg mL−1 and below in
CMT-12; average of 12 % increase with concentrations
of 3.1 μg mL−1 and below in D17 (p < 0.05). Green tea,
black pepper, and pomegranate [40 % punicosides] ex-
tracts required a concentration greater than 20 μg mL−1
to reduce cell proliferation (Table 2).
Turmeric extract (TE) and rosemary extract [70 % carnosic
acid] (RE) combination
The most effective and consistently synergistic combin-
ation was between TE and RE. No other dual extract
treatments were found to have considerable or consist-
ent synergy at any combination of extract across all
three cancer cell lines (data not shown for 4 negative
combinations). The combination of TE and RE resulted
in a decrease in the concentrations of each extract
needed to reach an IC50 in all three cell lines suggesting
a synergistic combination (Fig. 1a-c). The IC50 required
in combination (determined using equal concentra-
tions of extracts) was 2.9 μg mL−1 of each extract in
C2, 4.9 μg mL−1 of each extract in CMT-12, and
7.5 μg mL−1 of each extract in D17. Analysis using
Calcusyn software resulted in Combination Index (CI)
values below 0.9, indicating synergy, in treatment
concentrations at or below 12.5 μg mL−1 of each
extract in all three cell lines (Table 3A-C). With
treatment using this combination, a significant de-
crease in cell proliferation compared to vehicle con-
trol was first observed at a concentration of
1.7 μg mL−1 TE + 1.7 μg mL−1 RE in the C2 (IC28, p =
0.0001) and CMT-12 (IC13, p = 0.0019) cell lines, and at a
concentration of 3.1 μg mL−1 TE + 3.1 μg mL−1 RE in the
D17 cell line (IC11, p = 0.0073). Once a concentration of
6.3 μg mL−1 TE + 6.3 μg mL−1 RE was reached in the C2
cell line (p < 0.0001) and a concentration of 12.5 μg mL−1
TE + 12.5 μg mL−1 RE in the CMT12 (p = 0.0052) and
D17 (p = 0.0041) cell lines, further increases in inhibition
were not detected with higher concentrations when com-
pared to DMSO treatment alone.
Natural extracts and chemotherapy interaction on growth
inhibition of cancer cell lines
The CI values generated for the C2 cell line with dual
extract treatment in the presence of toceranib phosphate
at the IC25 (Table 4A) and IC50 (Table 4B) showed that
when both extracts were added at 0.8 or 1.7 μg mL−1
there was a mild antagonistic to additive effect, while at
3.1 μg mL−1 of both extracts there was a definitive addi-
tive effect. When either extract was added at 6.3 μg mL−1
there was a definitive synergistic effect with toceranib
phosphate regardless of the amount of the other extract.












IC50 (μg/mL) IC50 (μg/mL) IC50 (μg/mL) IC50 (μg/mL) IC50 (μg/mL) IC50
C2 11.5 48.5 11.9 4.8 21.8 12.5 nM (6.2 ng mL−1)
CMT-12 20.4 40.9 13.0 9.1 34.5 0.3 μM (163.1 ng mL−1)
D17 47.8 93.8 13.6 12.3 36.5 0.5 μM (271.8 ng mL−1)
Values were determined by averaging duplicate wells in four independent experiments and using Probit analysis
aC2 treated with toceranib phosphate, CMT-12 and D17 treated with doxorubicin hydrochloride
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Fig. 1 Synergistic combinations of TE and RE. Percent proliferating cells of control are represented as mean ± SEM and were determined by MTT
assay on C2 (a), CMT-12 (b), and D17 (c) cell lines. TE and RE were used individually (dashed lines) or in combination at equal concentrations
(solid line) at doses ranging from 0.8 to 25 μg mL−1. Lowest dose that induced a significant (p < 0.05) decrease in percent proliferation compared
to DMSO control indicated by + (TE alone), # (RE alone), and ^ (dual extract combination)
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At the IC75 (Table 4C) of toceranib phosphate, syn-
ergy was only seen when both extracts were used at
6.3 μg mL−1, all other combinations produced an
additive or mildly antagonistic effect. When the
CMT-12 cell line was treated with an IC25 of doxo-
rubicin hydrochloride, synergy or an additive effect
could be seen when both extracts were used at a
concentration of 1.7 μg mL−1 or higher and antagon-
ism was seen when either extract was used at a con-
centration of 0.8 μg mL−1 (Table 4D). When
doxorubicin hydrochloride was used at the IC50
(Table 4E) or IC75 (Table 4F), if either extract was
used at 3.1 μg mL−1 or lower there was modest an-
tagonism. When extracts were combined at concen-
trations of 3.1 μg mL−1 or higher there was an
additive or synergistic effect. The D17 cell line
showed a modest additive or synergistic effect at any
combination of extracts when used with any IC of
doxorubicin (Table 4G-I) in general, with the weak-
est effect at the IC50 with possible mild antagonism
at 1.7 and 3.1 μg mL−1 (Table 4H).
Cytotoxic activity of TE and RE against cancer cell lines
without affecting normal cells
Figure 2 shows that individual extracts at 6.3 μg mL−1 or
a combination of 3.1 μg mL−1 TE and 3.1 μg mL−1 RE
did not induce a significant decrease in cell viability in
the control primary cells, Canine Dermal Fibroblasts
(CDF). In comparison, the three cancer cell lines were
also assayed using the same conditions. These concen-
trations did not induce cytotoxicity on the D17 cell line,
while the C2 and CMT-12 cell lines had a significant
Table 3 Combination Index for two extract treatment
Combination Index (CI) values for C2 (A), CMT-12 (B), and D17 (C) cell lines treated with TE and RE in combination at doses of 0.8, 1.7, 3.1, 6.3, 12.5, and 25.0 μg
mL−1. CI values ≤ 0.9 indicate synergism (bold values), a CI value >0.9 and <1.1 indicates an additive effect, and CI values ≥1.1 indicate antagonism (italicized
values). NP = no calculation possible due to antagonism with single extract alone (RE)
Levine et al. BMC Veterinary Research  (2016) 12:159 Page 6 of 11
decrease in cell viability when treated with 6.3 μg mL−1
TE alone (29 and 36 %, respectively p < 0.01) or with the
combination of 3.1 μg mL−1 each extract (26 and 51 %,
respectively p < 0.01).
Discussion
The use of bioactive polyphenol and/or carotenoids from
feed ingredients is well studied in human cancer cells,
and there may be efficacy in the utilization of many of
these bioactive components, particularly in combination
[28, 29]. In the current study we surveyed five extracts
which were selected based an initial screen of feed ingre-
dients most abundant anti-proliferative compounds that
could hinder cell proliferation at 25 μg mL−1, which
would represent the high end of physiologically achiev-
able concentration of approximately 10–20 μM for the
presumed main component in the extracts examined
[14, 15, 30]. Our results indicate that TE was the most
potent at inhibiting proliferation at low microgram
quantities. To further confirm the single extracts and
potential interaction of TE and RE observed in the MTT
assay, trypan blue exclusion assays were also performed
to assess viable versus non-viable cells. The modest dif-
ferences in terms of inhibitory effects when comparing
the trypan blue and MTT assays may be a reflection of
membrane permeability and cytotoxicity being measured
with the trypan blue assay versus metabolic cellular ac-
tivity being measured with the MTT assay. This is par-
ticularly evident in the D17 cell line which was less
sensitive than the C2 or CMT-12 cell lines, showing
diminished activity on MTT proliferative assays and no
increase in cell death in the trypan blue assay, suggesting
a diminished cell proliferation response rather than cell
death response. The response of C2 and CMT-12 cell
lines showed that the combination effect of TE with RE
was equal, if not superior, in diminishing cell growth as
Table 4 Combinatorial effects of TE/RE and chemotherapy on tumor cell proliferation
Combination Index (CI) values on C2 (A-C), CMT-12 (D-F), and D17 (G-I) cell lines treated with TE and RE in combination at doses of 0.8, 1.7, 3.1, and 6.3 μg mL−1
in the presence of chemotherapeutic agents. Toceranib phosphate used for C2 cell line at (A) IC25 dose of 6.3 nM, (B) IC50 dose of 12.5 nM, and (C) IC75 dose of
12.5 nM; doxorubicin hydrochloride was used for the CMT-12 cell line at (D) IC25 dose of 0.1 μM, (E) IC50 dose of 0.3 μM, and (F) IC75 dose of 1 μM; doxorubicin
hydrochloride was used for the D17 cell line at (G) IC25 dose of 0.3 μM, (H) IC50 dose of 0.5 μM, and (I) IC75 dose of 2 μM. CI values ≤ 0.9 indicate synergism
(bold values), a CI value >0.9 and <1.1 indicates an additive effect, and CI values ≥1.1 indicate antagonism (italicized value)
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well as increasing the number of non-viable cells than
treatment with TE alone, suggesting synergy in this
treatment strategy.
Of the two plant extracts that were most effective, TE,
which contains 87 % curcuminoids, showed the most
potent anti-proliferative effects. These effects could be
seen at a concentration below 15 μg mL−1 in all cell lines
examined. The high potency of curcumin may be related
to its binding affinity for at least 30 different proteins
[31]. The anti-proliferative effects have been examined
in cell culture models of nearly every type of neoplastic
condition including leukemia, breast, prostate, bladder,
melanocyte, skin, ovarian, hepatic and uterine cancer
cells [32]. In most cell-based models, low micromolar
concentrations of curcumin thought to be physiological,
affect various intracellular pathways ranging from tran-
scriptional activation, to induction of apoptosis, to halt-
ing of the cell cycle [33]. These include: transcriptional
activators AP-1, Nf-kB, β-catenin, STAT-3, hypoxia in-
duced factor-1, and notch-1; receptor signaling cascades
EGF, HER2, VEGF, PDGF, IGF, and FGF; all three major
MAP Kinases ERK1/2, p38, and JNK and protein kinase
C; intrinsic mitochondrial apoptosis induction by changes
in mitochondrial membrane permeability via Bcl-2 and
Bax family member proteins are also documented [34].
The wide array of molecular targets has led to over 100
clinical trials in humans to study the use of curcumin to
treat various pathologies from obesity related diseases to
neurological diseases to various models of neoplastic con-
ditions [35]. Although curcumin and turmeric extracts are
effective in vitro, the bioavailability and absorption of cur-
cuminoids is somewhat limited. Typically, less than 10 %
of curcumin is absorbed, even with aggressive treatment
regimens, leading to high nanomolar serum concentra-
tions in rodents and humans [36, 37]. The curcumin that
is absorbed is quickly glycosylated, sulfated, or hydroxyl-
ated, and it is unclear if these metabolites are as effective as
the unconjugated curcumin [38, 39]. Several approaches to
increase bioavailability are being examined including the
use of curcumin analogs [40], liposomal curcumin [41],
curcumin nanoparticles [42], and adjuvant therapy [54]
with bioavailability enhancers such as piperine from black
pepper extract [43]. These modifications have led to in-
creased blood curcumin concentrations and a half-life of
nearly 10 h. Recently, there have been several studies look-
ing into using whole turmeric extract mixtures instead of
pure curcumin alone. Specifically, extract formulations in-
cluding turmerones has led to increased solubility, absorp-
tion, and bioavailability [44]. Generally, treatment with
curcumin has exhibited no adverse side effects even at high
doses and because of this, a maximum tolerated dose has
not been established [45]. Only two canine studies have
been completed, with low oral dosing regimens of
4 mg kg−1 given orally twice a day showing no side effects
after 2 months of treatment [46, 47]. These studies did
not measure specifically measure bioavailability, but one
study was able to measure transcriptional changes after
20 days of curcumin supplementation [46].
Rosemary extract rich in carnosic acid (RE) also gener-
ated interesting results considering the IC50 for cellular
proliferation is likely within physiological ranges, but
more specifically because of its synergistic effects with
TE. Rosmarinus officinalis contains several phenolic
compounds including carnosic acid, carnosol, and ros-
marinic acid [48]. In our study, as well as others, carno-
sic acid and carnosol were more potent in decreasing
cellular proliferation than rosmarinic acid in various
types of cancer cell lines at concentrations below 20 μM
[49, 50]. Carnosic acid and carnosol have been shown to
have several mechanisms of action including cell cycle
Fig. 2 Cytotoxic activity of TE, RE, and combination on tumor cell lines versus normal cells. Percent viable cells determined by trypan blue
exclusion assay are represented as mean ± SEM in comparison with DMSO vehicle treatment. Within each cell line, means not sharing the same
letter are significantly different (Tukey HSD, p < 0.05). NS = Not significant
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arrest, induction of apoptosis, free radical scavenging, in-
hibition of metastatic markers, and inhibition of P-
glycoprotein mediated drug efflux [51–53]. Intracellular
pathways affected include inhibition of PI3-Kinase/AKT/
Nf-kB signaling [54], down-regulation of cyclins A and B
[55], induction of apoptosis by decreases in Bcl-2 [56],
and inhibition of all three major MAP Kinases ERK1/2,
p38, and JNK [57]. In rodent studies, the use of a topical
[58] or oral [59] rosemary extract has been well tolerated
and effective. Toxicity studies in rats have shown that up
to 3 g kg−1 of rosemary oil is acceptable [60, 61] and bio-
logically relevant levels of around 10 μM can be reached
through dietary administration [62], however canine
studies are lacking.
We found synergy between TE and RE, which agrees
with previous in vitro studies using the same combin-
ation [63, 64]. While RE alone was only effective at con-
centrations above 6.3 μg mL−1 in all three cancer cell
lines, its use with TE significantly decreased the concen-
trations needed to reduce cell proliferation. In all three
tumor cell lines, these extracts worked synergistically at
concentrations between 1 – 10 μg mL−1 of each extract.
When used in combination, extrapolation of our data ac-
counting for the percentage of the compound of interest
(curcumin and carnosic acid) suggest that the IC50 is
6.8 μM curcumin and 7.6 μM carnosic acid for C2,
12 μM curcumin and 13 μM carnosic acid for CMT-12,
and 18 μM curcumin and 20 μM carnosic acid for D17.
Neither of the extracts, when used alone or in combin-
ation, showed effects on cell viability in the normal ca-
nine dermal fibroblasts, suggesting the effects on normal
cell death or proliferation is minimal. Other control cells
were considered, including the canine fibroblast A-72
tumor cell line and Madin-Darby Canine Kidney (MDCK)
epithelial cells, but due to the highly proliferative and po-
tentially tumorigenic nature of these cell lines they were
not used. CDF cells were chosen due to their seemingly
normal phenotype, ease of maintenance, and commercial
availability. Further studies could examine the effects on
primary lymphocytes or epithelial cells, but these cell types
were not available at the time this study was completed.
When the C2 cell line was incubated with the TE/RE
combination in the presence of toceranib phosphate, a
synergistic or additive effect was seen when either
extract was used at 6.3 μg mL−1, or when TE was used
at 3.1 μg mL−1 or higher. When the CMT-12 cell line
was treated with the TE/RE combination in the presence
of doxorubicin hydrochloride, there was a modest antag-
onistic effect at lower concentrations of both extracts
when used alone (below 3.1 μg mL−1 of each), but a syn-
ergistic or additive effect could be seen with a higher
concentration of 6.3 μg mL−1 of both extracts individu-
ally. The D17 cell line showed considerable additive and
synergistic effects with all extract combinations at the
IC25 and IC75 of doxorubicin hydrochloride in general.
Mild antagonism was seen when extracts were used at
3.1 μg mL−1 or lower, but this was diminished or absent
when either extract reached a concentration of
6.3 μg mL−1. Considering these findings, further testing
of TE and RE with other chemotherapies to ensure simi-
lar synergy, additive, or antagonistic effects is warranted.
Furthermore, considering the lack of basic pharmacokin-
etics with oral TE and RE canine studies are needed to
examine whether there feed ingredients would have any
utility. The synergistic effect of these compounds with
chemotherapies is necessary, not only due to the potential
to decrease the administered dose for treatment, but also
to examine alterations in chemotherapy metabolism.
Other extracts examined in the MTT assay were
VetPerine® (piperine), pomegranate extracts and green
tea extracts. Effective IC50 for these extracts across the
cell lines were typically above 25 μg mL−1 which would
be considered supraphysiological. This takes into ac-
count that most animals cannot reach concentrations
greater than approximately 10–20 μM of any specific
bioactive component from these extracts when used at
relatively large doses for any significant period of time.
That said, these compounds were also tested for synergy,
antagonism, or additive effects and were not observed to
increase TE or RE effectiveness (data not shown) and
were discounted for further examination with commonly
used chemotherapeutics.
Conclusions
This study of commonly used feed ingredients showed
that a combination of TE and RE diminished the growth
of cancer cells. This synergistic effect was observed at
10 μg mL−1 and below indicating a potential for physio-
logical effects, however in vivo pharmacokinetic and effi-
cacy studies are needed. Although we are unsure of the
bioactive molecules inducing these effects, the high con-
centrations of curcuminoids and carnosic acid are likely
involved. The anti-proliferative effects of chosen chemo-
therapeutics were not hindered when these extracts were
used in combination at concentrations of 3.1 and
6.3 μg mL−1 across a range of chemotherapeutic concen-
trations. Further testing of other chemotherapies with
these specific extracts is warranted to ensure no distinct
antagonism is evident. In addition, further examination
of the potential apoptotic effects and cellular pathways
affected by these extracts individually and in combin-
ation may be fruitful in determining the similarities and
differences of their effects between cell lines.
Abbreviations
CDF, canine dermal fibroblasts; CI, combination index; DMSO, dimethyl
sulfoxide; IC50, 50 % inhibitory concentration; MTT, 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide; RE, rosemary extract [70 % carnosic
acid]; TE, Turmeric extract
Levine et al. BMC Veterinary Research  (2016) 12:159 Page 9 of 11
Acknowledgements
We are grateful to the University of California San Francisco, especially Dr.
Warren Gold and Dr. George Caughey, for supplying the C2 canine
mastocytoma cell line; and to Auburn University, especially Dr. R. Curtis Bird,
for supplying CMT-12 canine mammary gland carcinoma cell line.
Funding
The aforementioned study was funded by Royal Canin. Royal Canin (JB and
VB) collaborated on the study design and interpretation of data collected.
Availability of data and materials
Additional data regarding combinations of extracts will be made available
upon request to corresponding author.
Authors’ contributions
CBL carried out the technical experimentation, performed statistical analysis,
and drafted the manuscript. JB and VB conceived the study and participated
in its design and coordination as well as manuscript editing. JJW helped to
conceive the study, supervised the study, and helped to draft the
manuscript. All authors have read and approved the final manuscript.
Competing interests
JB and VB are employed by Royal Canin. JJW receives honoraria from and is
on the advisory council for Nestle Purina, Annamaet Petfoods, and Mars Inc.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable. Cell culture study institutional biosafety committee # 15902.
Author details
1Department of Clinical Sciences, Cornell University College of Veterinary
Medicine, Veterinary Medical Center C2-009, Ithaca 14853, NY, USA. 2Royal
Canin Research Center, Airmargues, France.
Received: 13 February 2016 Accepted: 16 July 2016
References
1. Adams VJ, Evans KM, Sampson J, Wood JLN. Methods and mortality results
of a health survey of purebred dogs in the UK. J Small Anim Pract.
2010;51:512–24.
2. Bronson RT. Variation in age at death of dogs of different sexes and breeds.
Am J Vet Res. 1982;43:2057–9.
3. Fleming JM, Creevy KE, Promislow DE. Mortality in North American dogs
from 1984 to 2004: an investigation into age-, size-, and breed-related
causes of death. J Vet Intern Med. 2011;25:187–98.
4. Dobson JM. Breed-predispositions to cancer in pedigree dogs. ISRN
Veterinary Science. 2013;2012:1–23.
5. Kelsey JL, Moore AS, Glickman LT. Epidemiologic studies of risk factors for
cancer in pet dogs. Epidemiol Rev. 1998;20:2014–17.
6. Hume KR, Johnson JL, Williams LE. Adverse effects of concurrent carboplatin
chemotherapy and radiation therapy in dogs. J Vet Intern Med. 2008;23:24–30.
7. Lana SE, Kogan LR, Crump KA, Graham JT, Robinson NG. The use of
complementary and alternative therapies in dogs and cats with cancer.
J Am Anim Hosp Assoc. 2006;42:361–5.
8. Newman DJ, Cragg GM. Natural products as sources of new drugs over the
30 years from 1981–2010. J Nat Prod. 2012;75:311–35.
9. Nobili S, Lippi D, Witort E, Donnini M, Bausi L, Mini E, Capaccioli S. Natural
compounds for cancer treatment and prevention. Pharmacol Res.
2009;59(6):365–78.
10. Yang CS, Landau JM, Huang M, Newmark HL. Inhibition of carcinogenesis
by dietary polyphenolic compounds. Annu Rev Nutr. 2001;21:381–406.
11. Aggarwal BB, Takada Y, Oommen OV. From chemoprevention of
chemotherapy: common targets and common goals. Expert Opin Investig
Drugs. 2004;13:1327–38.
12. González-Vallinas M, González-Castejón M, Rodríguez-Casado A, Ramírez de
Molina A. Dietary phytochemicals in cancer prevention and therapy: a
complementary approach with promising perspectives. Nutr Rev.
2013;71:585–99.
13. Helmerick EC, Loftus JP, Wakshlag JJ. The effects of baicalein on canine
osteosarcoma cell proliferation and death. Vet Comp Oncol. 2014;12:299–309.
14. Wakshlag JJ, Balkman CE. Effects of lycopene on proliferation and death of
canine osteosarcoma cells. Am J Vet Res. 2010;71:1362–70.
15. Wakshlag JJ, Balkman CA, Morgan SK, McEntee MC. Evaluation of the
protective effects of all-trans-astaxanthin on canine osteosarcoma cell lines.
Am J Vet Res. 2010;71:89–96.
16. Fresco P, Borges F, Diniz C, Marques MPM. New insights on the anticancer
properties of dietary polyphenols. Med Res Rev. 2006;26:747–66.
17. Potter JD. Cancer prevention: epidemiology and experiment. Cancer Lett.
1997;114:7–9.
18. Ramos S. Effects of dietary flavonoids on apoptotic pathways related to
cancer chemoprevention. J Nutritional Biochemistry. 2007;18:427–42.
19. Raghavan M, Knapp DW, Bonney PL, Dawson MH, Glickman LT. Evaluation
of the effect of dietary vegetable consumption on reducing risk of
transitional cell carcinoma of the urinary bladder in Scottish Terriers. JAVMA.
2005;227:94–100.
20. Thomas R, Williams M, Sharma H, Chaudry A, Bellamy P. A double-blind,
placebo-controlled randomized trial evaluating the effect of a polyphenol-
rich whole food supplement on PSA progression in men with prostate
cancer—the U.K. NCRN Pomi-T study. Prostate Cancer Prostatic Dis.
2014;17(2):180–6.
21. He ZY, Shi CB, Wen H, Li FL, Wang BL, Wang J. Upregulation of p53
expression in patients with colorectal cancer by administration of curcumin.
Cancer Invest. 2011;29(3):208–13.
22. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD,
Giardiello FM. Combination treatment with curcumin and quercetin of
adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol.
2006;4(8):1035–8.
23. Gressmayr PC, Gauthier M, Barber LG, Cotter SM. Mushroom-derived
maitake PETfraction as single agent for the treatment of lymphoma in dogs.
J Vet Intern Med. 2007;21(6):1409–12.
24. Ogilvie GK, Fettman MJ, Mallinckrodt CH, Walton JA, Hansen RA, Davenport
DJ, et al. Effect of fish oil, arginine, and doxorubicin chemotherapy on
remission and survival time for dogs with lymphoma: a double-blind,
randomized placebo-controlled study. Cancer. 2000;88:1916–28.
25. Association of American Feed Control Officials, Inc. 2015 Official Publication. 2015.
26. Vega-Avila E, Pugsley MK. An overview of colorimetric assay methods used
to assess survival or proliferation of mammalian cells. Proc West Pharmacol
Soc. 2011;54:10–4.
27. Chou TC. Drug combination studies and their synergy quantification using
the Chou-Talalay method. Cancer Res. 2010;70:440–6.
28. Liu RH. Health-promoting components of fruits and vegetables in the diet.
Adv Nutr. 2013;4 Suppl 3:384–92.
29. Liu RH. Potential synergy of phytochemicals in cancer prevention:
mechanism of action. J Nutr. 2004;134 Suppl 12:3479–85.
30. Manach C, Williamson G, Morand C, Scalbert A, Rémésy C. Bioavailability
and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability
studies. Am J Clin Nutr. 2005;81(1 Suppl):230S–42S.
31. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in
chronic diseases: an age-old spice with modern targets. Trends Pharmacol
Sci. 2009;30:85–94.
32. Shishu MM. Comparative bioavailability of curcumin, turmeric, and
Biocurcumax™ in traditional vehicles using non-everted rat intestinal sac
model. J Funct Foods. 2010;2:60–5.
33. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation,
invasion, angiogenesis and metastasis of different cancers through interaction
with multiple cell signaling proteins. Cancer Lett. 2008;269:199–225.
34. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many
ways can curry kill tumor cells selectively? AAPS J. 2009;11:495–510.
35. Clinical Trials. US National Library of Medicine, Bethesda. 2000. https://
clinicaltrials.gov/ct2/home. Accessed 02 June 2015.
36. Lao CD, Ruffin 4th MT, Normolle D, Heath DD, Murray SI, Bailey JM, et al.
Dose escalation of a curcuminoid formulation. BMC Complement Altern
Med. 2006;6:10.
37. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, et al.
Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in
patients with colorectal cancer. Clin Cancer Res. 2001;7:1894–900.
38. Asai A, Miyazawa T. Occurrence of orally administered curcuminoid as
glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sci.
2000;67:2785–93.
Levine et al. BMC Veterinary Research  (2016) 12:159 Page 10 of 11
39. Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of
curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione)
in the rat. Xenobiotica. 1978;8:761–8.
40. Vyas A, Dandawate P, Padhye S, Ahmad A, Sarkar F. Perspectives on new
synthetic curcumin analogs and their potential anticancer properties. Curr
Pharm Des. 2013;19:2047–69.
41. Storka A, Vcelar B, Klickovic U, Gouya G, Weisshaar S, Aschauer S, et al.
Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy
humans. Int J Clin Pharmacol Ther. 2015;53:54–65.
42. Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, et al.
Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a
potential anticancer agent with improved bioavailability, in healthy human
volunteers. Cancer Chemother Pharmacol. 2012;69:65–70.
43. Patil UK, Singh A, Charkraborty AK. Role of piperine as a bioavailability
enhancer. International Journal of Recent Advances in Pharmaceutical
Research. 2011;4:16–23.
44. Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S. A pilot cross-over
study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax),
a novel bioenhanced preparation of curcumin. Indian J Pharm Sci.
2008;70:445–9.
45. Johnson JJ, Mukhtar H. Curcumin for chemoprevention of colon cancer.
Cancer Lett. 2007;255:170–81.
46. Innes JF, Fuller CJ, Grover ER, Kelly AL, Burn JF. Randomised, double-blind,
placebo-controlled parallel group study of P54FP for the treatment of dogs
with osteoarthritis. Vet Rec. 2003;152:457–60.
47. Colitti M, Gaspardo B, Della Pria A, Scaini C, Stefanon B. Transcriptome
modification of white blood cells after dietary administration of curcumin
and non-steroidal anti-inflammatory drug in osteoarthritic affected dogs.
Vet Immunol Immunopathol. 2012;147:136–46.
48. Borrás Linares I, Stojanović Z, Quirantes-Piné R, Arráez-Román D, Švarc-Gajić
J, Fernández-Gutiérrez A, Sequra-Carretero A. Rosmarinus officinalis leaves as
a natural source of bioactive compounds. Int J Mol Sci. 2014;15:20585–606.
49. Yesil-Celiktas O, Sevimli C, Bedir E, Vardar-Sukan F. Inhibitory effects of
rosemary extracts, carnosic acid and rosmarinic acid on the growth of
various human cancer cell lines. Plant Foods Hum Nutr. 2010;65:158–63.
50. Tai J, Cheung S, Wu M, Hasman D. Antiproliferation effect of Rosemary
(Rosmarinus officinalis) on human ovarian cancer cells in vitro.
Phytomedicine. 2012;19:436–43.
51. Ngo SN, Williams DB, Head RJ. Rosemary and cancer prevention preclinical
perspectives. Crit Rev Food Sci Nutr. 2011;51:946–54.
52. Ðilas S, Knez Ž, Četojević-Simin D, Tumbas V, Škerget M, Čanadanović-
Brunet J, Ćetković G. In vitro antioxidant and antiproliferative activity of
three rosemary (Rosmarinus officinalis L.) extract formulations. Int J Food Sci
Tehnol. 2012;47:2052–62.
53. Plouzek CA, Ciolino HP, Clarke R, Yeh GF. Inhibition of P-glycoprotein
activity and reversal of multidrug resistance in vitro by rosemary extract.
Eur J Cancer. 1999;35:1541–5.
54. Kar S, Palit S, Ball WB, Das PK. Carnosic acid modulates Akt/IKK/NF-kB signaling
by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in
human prostate carcinoma PC-3 cells. Apoptosis. 2012;17:735–47.
55. Visanji JM, Thompson DG, Padfield PJ. Induction of G2/M phase cell cycle
arrest by carnosol and carnosic acid is associated with alteration of cyclin A
and cyclin B1 levels. Cancer Lett. 2006;237:130–6.
56. Dorrie J, Sapala K, Zunino SJ. Carnosol-induced apoptosis and downregulation
of Bcl-2 in B-lineage leukemia cells. Cancer Lett. 2001;170:33–9.
57. Tsai CW, Lin CY, Lin HH, Chen JH. Carnosic acid, a rosemary phenolic
compound, induces apoptosis through reactive oxygen species-mediated
p38 activation in human neuroblastoma IMR-32 cells. Neurochem Res.
2011;36:2442–51.
58. Huang MT, Ho CT, Wang ZY, Ferraro T, Lou YR, Stauber K, Ma W, et al.
Inhibition of skin tumorigenesis by rosemary and its constituents carnosol
and ursolic acid. Cancer Res. 1994;54:701–8.
59. Manoharan S, Vasanthaselvan M, Silvan S, Baskaran N, Kumar Singh A,
Vinoth KV. Carnosic acid: a potent chemopreventive agent against oral
carcinogenesis. Chem Biol Interact. 2010;188:616–22.
60. Aquilina G, Bories G, Chesson A, Cocconcelli PS, de Knecht J, Dierick NA, et
al. Statement on the safety and efficacy of the product ‘Rosemary extract
liquid of natural origin’ as a technological feed additive for dogs and cats.
European Food Safety Authority J. 2012;10:2526.
61. Aguilar F, Autrup H, Barlow S, Castle L, Crebelli R, Dekant W, et al. Use of
rosemary extracts as a food additive, scientific opinion of the panel on food
additives, flavourings, processing aids and materials in contact with food.
The European Food Safety Authority Journal. 2008;721:1–29.
62. Romo Vaguero M, García Villalba R, Larrosa M, Yáñez-Gascón MJ, Fromentin
E, Flanagan J, et al. Bioavailability of the major bioactive diterpenoids in a
rosemary extract: metabolic profile in the intestine, liver, plasma, and brain
of Zucker rats. Mol Nutr Food Res. 2013;57:1834–46.
63. Pesakhov S, Khanin M, Studzinski GP, Danilenko M. Distinct combinatorial
effects of the plant polyphenols curcumin, carnosic acid, and silibinin on
proliferation and apoptosis in acute myeloid leukemia cells. Nutr Cancer.
2010;62:811–24.
64. Einbond LS, Wu HA, Kashiwazaki R, He K, Roller M, Su T, et al. Carnosic acid
inhibits the growth of ER-negative human breast cancer cells and
synergizes with curcumin. Fitoterapia. 2012;83:1160–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Levine et al. BMC Veterinary Research  (2016) 12:159 Page 11 of 11
